Abstract
Immune checkpoint blockade (ICB) is associated with improved survival in patients with metastatic melanoma (MM). Despite this, many patients have limited clinical benefit, and there is ongoing attrition amongst responders. Moreover, ICB is associated with auto-immune toxicity. Peripheral biomarkers can help early identification of non-responders, as well as assist in treatment stratification. Recent evidence suggests that myeloid populations may play a role in modulating ICB response, but this has yet to be full defined at the transcriptomic level.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.